150 related articles for article (PubMed ID: 25890750)
1. Enhanced immunostimulatory effects of DNA-encapsulated peptide hydrogels.
Medina SH; Li S; Howard OM; Dunlap M; Trivett A; Schneider JP; Oppenheim JJ
Biomaterials; 2015; 53():545-53. PubMed ID: 25890750
[TBL] [Abstract][Full Text] [Related]
2. Amino acid sequence determines the adjuvant potency of a D-tetra-peptide hydrogel.
Zhang Y; Hu Z; Li X; Ding Y; Zhang Z; Zhang X; Zheng W; Yang Z
Biomater Sci; 2022 Jun; 10(12):3092-3098. PubMed ID: 35522938
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
[TBL] [Abstract][Full Text] [Related]
4. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
5. Combined encapsulation of a tumor antigen and immune cells using a self-assembling immunostimulatory DNA hydrogel to enhance antigen-specific tumor immunity.
Umeki Y; Saito M; Kusamori K; Tsujimura M; Nishimura M; Takahashi Y; Takakura Y; Nishikawa M
J Control Release; 2018 Oct; 288():189-198. PubMed ID: 30219278
[TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis.
Wang Z; Liang C; Shi F; He T; Gong C; Wang L; Yang Z
Nanoscale; 2017 Sep; 9(37):14058-14064. PubMed ID: 28895610
[TBL] [Abstract][Full Text] [Related]
7. Serum Protein Adsorption Modulates the Toxicity of Highly Positively Charged Hydrogel Surfaces.
Yamada Y; Fichman G; Schneider JP
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8006-8014. PubMed ID: 33590757
[TBL] [Abstract][Full Text] [Related]
8. Rational design of charged peptides that self-assemble into robust nanofibers as immune-functional scaffolds.
Zhang H; Park J; Jiang Y; Woodrow KA
Acta Biomater; 2017 Jun; 55():183-193. PubMed ID: 28365480
[TBL] [Abstract][Full Text] [Related]
9. In vivo administration of the frog skin peptide frenatin 2.1S induces immunostimulatory phenotypes of mouse mononuclear cells.
Pantic JM; Radosavljevic GD; Jovanovic IP; Arsenijevic NN; Conlon JM; Lukic ML
Peptides; 2015 Sep; 71():269-75. PubMed ID: 25861850
[TBL] [Abstract][Full Text] [Related]
10. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
[TBL] [Abstract][Full Text] [Related]
11. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
[TBL] [Abstract][Full Text] [Related]
12. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
Ferrone CR; Perales MA; Goldberg SM; Somberg CJ; Hirschhorn-Cymerman D; Gregor PD; Turk MJ; Ramirez-Montagut T; Gold JS; Houghton AN; Wolchok JD
Clin Cancer Res; 2006 Sep; 12(18):5511-9. PubMed ID: 17000687
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
14. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
Xu Z; Moyle PM
Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
[TBL] [Abstract][Full Text] [Related]
15. Safety and biocompatibility of injectable vaccine adjuvants composed of thermogelling block copolymer gels.
Adams JR; Senapati S; Haughney SL; Wannemuehler MJ; Narasimhan B; Mallapragada SK
J Biomed Mater Res A; 2019 Aug; 107(8):1754-1762. PubMed ID: 30972906
[TBL] [Abstract][Full Text] [Related]
16. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production.
Fernando GJ; Stenzel DJ; Tindle RW; Merza MS; Morein B; Frazer IH
Vaccine; 1995; 13(15):1460-7. PubMed ID: 8578827
[TBL] [Abstract][Full Text] [Related]
17. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA.
Morishita M; Takahashi Y; Matsumoto A; Nishikawa M; Takakura Y
Biomaterials; 2016 Dec; 111():55-65. PubMed ID: 27723556
[TBL] [Abstract][Full Text] [Related]
18. Design of self-assembling peptide hydrogelators amenable to bacterial expression.
Sonmez C; Nagy KJ; Schneider JP
Biomaterials; 2015 Jan; 37():62-72. PubMed ID: 25453938
[TBL] [Abstract][Full Text] [Related]
19. Injectable and Pathogen-Mimicking Hydrogels for Enhanced Protective Immunity against Emerging and Highly Pathogenic Influenza Virus.
Noh HJ; Noh YW; Heo MB; Kim EH; Park SJ; Kim YI; Choi YK; Lim YT
Small; 2016 Dec; 12(45):6279-6288. PubMed ID: 27671946
[TBL] [Abstract][Full Text] [Related]
20. Peptide amphiphile nanoparticles enhance the immune response against a CpG-adjuvanted influenza antigen.
Zope H; Quer CB; Bomans PH; Sommerdijk NA; Kros A; Jiskoot W
Adv Healthc Mater; 2014 Mar; 3(3):343-8. PubMed ID: 23983195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
